SV

Street Verdict

Analyst Scorecard

A record of what Religare Broking Analysis said publicly, with the source. Not advice.

Pending — not yet graded
“Glenmark Pharma has broken out of an 8-month consolidation and a downward trendline, signaling further upside potential. Short-to-medium term traders can buy the stock, targeting ₹1,940 in the next 2-4 months, supported by positive technical indicators and sector outperformance.”
Glenmark Pharmaceuticals LtdBullishCalled 12 Jun 2025
Verdict:PENDING

How this call is judged

A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.

No entry price is stated, so the call starts at the first close after it was published.

Target ₹1,940, as stated.

Window: 120 days, the time frame the call states ("2-4 months").

Window still open: no verdict until a close reaches a level or the window ends.

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Tracking Glenmark Pharmaceuticals Ltd since this call

1-year tracking window
Read the original articleSee Religare Broking Analysis’s full track record